The End of Priority Review Vouchers? Reactions to Novarits' Ilaris Panel and Incentives for Tropical Disease Research

A supplemental BLA submitted by Novartis is the first product to use a priority review voucher to support the review. After a rejection by an advisory committee, will it also be the last? Advocates for tropical disease reseach weigh in with perspectives on the vocuher and other incentives.